Reviva Pharmaceuticals (Nasdaq: RVPH) has announced positive topline results and successful completion of its pivotal Phase 3 RECOVER trial evaluating the efficacy, safety and tolerability…
The FDA has accepted Day One Biopharmaceuticals’ (Nasdaq: DAWN) New Drug Application (NDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma…
October 27, 2023
ImmunityBio Secures FDA Approval for BLA for Bladder Cancer Drug, New PDUFA Date Set
Immunotherapy company, ImmunityBio (Nasdaq: IBRX) has received FDA approval for its Biologics License Application (BLA) for N-803 for the treatment of Bacille Calmette-Guérin (BCG)-unresponsive non-muscle-invasive…
October 27, 2023
Pfizer and BioNTech Join Forces to Develop Combination Influenza and COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity…
October 26, 2023
Cybin Completes Acquisition to Become International Leader in Novel Psychedelic Therapeutics
Cybin, Inc, (NYSE American:CYBN) has completed its acquisition of Small Pharma, creating an international leader in clinical-stage novel psychedelic therapeutics. Together, the companies’ portfolios create…
October 26, 2023
Cassava Buoyed by New Alzheimer’s Drug Safety Finding
Cassava Sciences, Inc. (Nasdaq: SAVA) announced a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from a Phase 3 clinical…
October 25, 2023
BioStem Opens First Clinical Site in Diabetic Foot Ulcer Study
Leading regenerative medicine company, BioStem Technologies (OTC: BSEM) has opened the first site and commenced patient recruitment for its clinical trial, which will evaluate the…
October 25, 2023
BioXcel Therapeutics Receives Positive Findings from Data Integrity Audit, Shares Rise Nearly 20%
BioXcel Therapeutics (Nasdaq: BTAI) has received positive findings from an independent data integrity audit. No evidence of misconduct or fraud was found beyond the instance…
Specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX) has announced additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003…
The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic…
Biopharmaceutical company, Alzamend Neuro (Nasdaq: ALZN) has submitted an investigational new drug application to the FDA for the initiation of a Phase IIA clinical study…
October 23, 2023
ABVC Completes Initial Subject Recruitment in ADHD Drug Study
ABVC BioPharma (Nasdaq: ABVC) has completed the required subject recruitment for an interim analysis on its Phase IIb clinical study evaluating its PDC-1421 capsule as…